Efficacy of Linagliptin in Japanese type 2 diabetic patients in hemodialysis

Efficacy of Linagliptin in Japanese type 2 diabetic patients in hemodialysis - Linagliptin T2D patients in hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007716

Enrollment

100

Registered

2012-04-10

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese type 2 diabetic patients in hemodialysis

Interventions

Linagliptin5mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese type 2 diabetic patients in hemodialysis

Exclusion criteria

Exclusion criteria: type 1 diabetic patients insulin dependent diabetes mellitus patients with antiGAD antiody

Design outcomes

Primary

Measure	Time frame
glycated albumine	—

Secondary

Measure	Time frame
Nitrotyrosine oxidized LDL BNP	—

Countries

Japan

Contacts

Public ContactTakashi Nomiyama

Fukuoka University Department of Endocrinology and Diabetes Mellitus

tnomiyama@fukuoka-u.ac.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026